- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 790871, 11 pages
Extranodal NK/T-Cell Lymphoma: Toward the Identification of Clinical Molecular Targets
1INSERM U976, 75010 Paris, France
2Faculté des Sciences, Université Paris Diderot, 75013 Paris, France
3Immunologie, Oncologie, et Dermatologie, INSERM U976, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, Pavillon Bazin, 75475 Paris Cedex 10, France
4Department of Anatomic Pathology, Chang Gung Memorial Hospital, Gueishan 33305, Taiwan
5INSERM U955, 94010 Créteil, France
6Faculté de Médecine, Université Paris-Est Créteil, 94010 Créteil, France
7Groupe Henri-Mondor, Département de Pathologie, AP-HP, 94010 Créteil, France
Received 30 December 2010; Accepted 24 February 2011
Academic Editor: John E. Coligan
Copyright © 2011 Christian Schmitt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Swerdlow, E. Campo, N. Harris, E. Jaffe, and S. H. S. Pileri, WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues, International Agency of Research on Cancer (IARC), Lyon, France, 2008.
- W. Y. Au, D. D. Weisenburger, T. Intragumtornchai et al., “Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project,” Blood, vol. 113, no. 17, pp. 3931–3937, 2009.
- J. K. C. Chan, V. C. Sin, K. F. Wong et al., “Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm,” Blood, vol. 89, no. 12, pp. 4501–4513, 1997.
- J. Lee, H. P. Yeon, S. K. Won et al., “Extranodal nasal type NK/T-cell Lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy,” European Journal of Cancer, vol. 41, no. 10, pp. 1402–1408, 2005.
- E. Takahashi, N. Asano, C. Li et al., “Nodal T/NK-cell lymphoma of nasal type: a clinicopathological study of six cases,” Histopathology, vol. 52, no. 5, pp. 585–596, 2008.
- A. Aviles, L. Rodriguez, R. Guzman, A. Talavera, E. L. Garcia, and J. C. Diaz-Maqueo, “Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate,” Hematological Oncology, vol. 10, no. 3-4, pp. 141–147, 1992.
- J. K. C. Chan, C. S. Ng, P. K. Hui, S. T. H. Lo, and W. H. Lau, “Angiocentric T-cell lymphoma of the skin: an aggressive lymphoma distinct from mycosis fungoides,” American Journal of Surgical Pathology, vol. 12, no. 11, pp. 861–876, 1988.
- Y. Ishii, N. Yamanaka, and K. Ogawa, “Nasal T-cell lymphoma as a type of so-called “lethal midline granuloma”,” Cancer, vol. 50, no. 11, pp. 2336–2344, 1982.
- N. L. Harris, E. S. Jaffe, H. Stein et al., “A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group,” Blood, vol. 84, no. 5, pp. 1361–1392, 1994.
- J. F. Emile, M. L. Boulland, C. Haioun et al., “CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas,” Blood, vol. 87, no. 4, pp. 1466–1473, 1996.
- J. Suzumiya, M. Takeshita, N. Kimura et al., “Expression of adult and fetal natural killer cell markers in sinonasal lymphomas,” Blood, vol. 83, no. 8, pp. 2255–2260, 1994.
- P. Kanavaros, M. C. Lescs, J. Briere et al., “Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus,” Blood, vol. 81, no. 10, pp. 2688–2695, 1993.
- A. K. Ruskova, R. Thula, and G. T. C. Chan, “Aggressive natural killer-cell leukemia: report of five cases and review of the literature,” Leukemia and Lymphoma, vol. 45, no. 12, pp. 2427–2438, 2004.
- A. K. S. Chiang, K. Y. Wong, A. C. T. Liang, and G. Srivastava, “Comparative analysis of Epstein-Barr virus gene polymorphisms in nasal T/NK-cell lymphomas and normal nasal tissues: implications on virus strain selection in malignancy,” International Journal of Cancer, vol. 80, no. 3, pp. 356–364, 1999.
- J. Minarovits, L. F. Hu, S. Imai et al., “Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas,” Journal of General Virology, vol. 75, no. 1, pp. 77–84, 1994.
- A. Jaccard, N. Gachard, B. Marin et al., “Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study,” Blood, vol. 117, no. 6, pp. 1834–1839, 2011.
- J. R. Anderson, J. O. Armitage, and D. D. Weisenburger, “Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations,” Annals of Oncology, vol. 9, no. 7, pp. 717–720, 1998.
- H. Kohrt and R. Advani, “Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment biology and treatment,” Leukemia and Lymphoma, vol. 50, no. 11, pp. 1773–1784, 2009.
- J. M. Vose, M. Neumann, and M. E. Harris, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008.
- C. Bossard, K. Belhadj, F. Reyes et al., “Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials,” Blood, vol. 109, no. 5, pp. 2183–2189, 2007.
- T. M. Kim, S. Y. Lee, Y. K. Jeon et al., “Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group,” Annals of Oncology, vol. 19, no. 8, pp. 1477–1484, 2008.
- W. Yong, W. Zheng, J. Zhu et al., “L-asparaginase in the treatment of refractory and relapsed extranodal NK/ T-cell lymphoma, nasal type,” Annals of Hematology, vol. 88, no. 7, pp. 647–652, 2009.
- V. E. Reyes Jr., T. Al-Saleem, V. G. Robu, and M. R. Smith, “Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature,” Leukemia Research, vol. 34, no. 1, pp. e50–e54, 2010.
- Y. Huang, A. De Reyniès, L. De Leval et al., “Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type,” Blood, vol. 115, no. 6, pp. 1226–1237, 2010.
- J. Iqbal, D. D. Weisenburger, A. Chowdhury et al., “Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro,” Leukemia, vol. 25, no. 2, pp. 348–358, 2011.
- T. Nagato, H. Kobayashi, K. Kishibe et al., “Expression of interleukin-9 in nasal natural killer/T-cell lymphoma cell lines and patients,” Clinical Cancer Research, vol. 11, no. 23, pp. 8250–8257, 2005.
- Y. Nakashima, H. Tagawa, R. Suzuki et al., “Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type,” Genes Chromosomes and Cancer, vol. 44, no. 3, pp. 247–255, 2005.
- S.-B. Ng, V. Selvarajan, G. Huang et al., “Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling,” Journal of Pathology, vol. 223, no. 4, pp. 496–510, 2011.
- T. Oka, T. Yoshino, K. Hayashi et al., “Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray,” American Journal of Pathology, vol. 159, no. 4, pp. 1495–1505, 2001.
- Y. Zhang, J. H. Ohyashiki, T. Takaku, N. Shimizu, and K. Ohyashiki, “Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection,” British Journal of Cancer, vol. 94, no. 4, pp. 599–608, 2006.
- H. E. Heslop, K. S. Slobod, M. A. Pule et al., “Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients,” Blood, vol. 115, no. 5, pp. 925–935, 2010.
- A. K. S. Chiang, Q. Tao, G. Srivastava, and F. C. S. Ho, “Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease,” International Journal of Cancer, vol. 68, no. 3, pp. 285–290, 1996.
- C. M. Bollard, S. Gottschalk, A. M. Leen et al., “Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer,” Blood, vol. 110, no. 8, pp. 2838–2845, 2007.
- C. P. Fox, T. A. Haigh, G. S. Taylor et al., “A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy,” Blood, vol. 116, no. 19, pp. 3695–3704, 2010.
- T. Kaneko, J. Fukuda, T. Yoshihara et al., “Nasal natural killer (NK) cell lymphoma: report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells,” British Journal of Haematology, vol. 91, no. 2, pp. 355–361, 1995.
- J. Tabiasco, A. Vercellone, F. Meggetto, D. Hudrisier, P. Brousset, and J. J. Fournié, “Acquisition of viral receptor by NK cells through immunological synapse,” Journal of Immunology, vol. 170, no. 12, pp. 5993–5998, 2003.
- H. Kimura, Y. Hoshino, H. Kanegane et al., “Clinical and virologic characteristics of chronic active Epstein-Barr virus infection,” Blood, vol. 98, no. 2, pp. 280–286, 2001.
- S. E. Straus, “The chronic mononucleosis syndrome,” Journal of Infectious Diseases, vol. 157, no. 3, pp. 405–412, 1988.
- J. I. Cohen, H. Kimura, S. Nakamura, Y. H. Ko, and E. S. Jaffe, “Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008,” Annals of Oncology, vol. 20, no. 9, pp. 1472–1482, 2009.
- M. L. Boulland, V. Meignin, K. Leroy-Viard et al., “Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer- cell lymphomas,” American Journal of Pathology, vol. 153, no. 4, pp. 1229–1237, 1998.
- J. Teruya-Feldstein, E. S. Jaffe, P. R. Burd et al., “The role of Mig, the monokine induced by interferon-γ, and IP-10, the interferon-γ-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease,” Blood, vol. 90, no. 10, pp. 4099–4105, 1997.
- P. Kanavaros, M. L. Boulland, B. Petit, B. Arnulf, and P. Gaulard, “Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tγδ phenotype, anaplastic morphology and CD30 expression,” Leukemia and Lymphoma, vol. 38, no. 3-4, pp. 317–326, 2000.
- E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of natural killer cells,” Nature Immunology, vol. 9, no. 5, pp. 503–510, 2008.
- C. Schmitt, B. Ghazi, and A. Bensussan, “NK cells and surveillance in humans,” Reproductive BioMedicine Online, vol. 16, no. 2, pp. 192–201, 2008.
- P. Parham, “MHC class I molecules and KIRS in human history, health and survival,” Nature Reviews Immunology, vol. 5, no. 3, pp. 201–214, 2005.
- Y. Suto, K. Maenaka, T. Yabe et al., “Chromosomal localization of the human natural killer cell class I receptor family genes to 19q13.4 by fluorescence in situ hybridization,” Genomics, vol. 35, no. 1, pp. 270–272, 1996.
- S. I. Khakoo and M. Carrington, “KIR and disease: a model system or system of models?” Immunological Reviews, vol. 214, no. 1, pp. 186–201, 2006.
- W. Haedicke, F. C. S. Ho, A. Chott et al., “Expression of CD94/NKG2A and killer immunoglobulin-like receptors in NK cells and a subset of extranodal cytotoxic T-cell lymphomas,” Blood, vol. 95, no. 11, pp. 3628–3630, 2000.
- C. W. Lin, W. H. Lee, C. L. Chang, J. Y. Yang, and S. M. Hsu, “Restricted killer cell immunoglobulin-like receptor repertoire without T-cell receptor γ rearrangement supports a true natural killer-cell lineage in a subset of sinonasal lymphomas,” American Journal of Pathology, vol. 159, no. 5, pp. 1671–1679, 2001.
- R. Lundell, L. Hartung, S. Hill, S. L. Perkins, and D. W. Bahler, “T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules,” American Journal of Clinical Pathology, vol. 124, no. 6, pp. 937–946, 2005.
- A. Dalloul, L. Laroche, M. Bagot et al., “Interleukin-7 is a growth factor for Sezary lymphoma cells,” Journal of Clinical Investigation, vol. 90, no. 3, pp. 1054–1060, 1992.
- N. Ortonne, S. Le Gouvello, H. Mansour et al., “CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome,” Journal of Investigative Dermatology, vol. 128, no. 2, pp. 465–472, 2008.
- E. Poszepczynska-Guigné, V. Schiavon, M. D'Incan et al., “CD158k/KIR3DL2 is a new phenotypic marker of sezary cells: relevance for the diagnosis and follow-up of sezary syndrome,” Journal of Investigative Dermatology, vol. 122, no. 3, pp. 820–823, 2004.
- F. Takei, K. L. McQueen, M. Maeda et al., “Ly49 and CD94/NKG2: developmentally regulated expression and evolution,” Immunological Reviews, vol. 181, pp. 90–103, 2001.
- C. W. Lin, Y. H. Chen, Y. C. Chuang, T. Y. Liu, and S. M. Hsu, “CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma,” Blood, vol. 102, no. 7, pp. 2623–2631, 2003.
- L. A. Fernandez, B. Pope, C. Lee, and E. Zayed, “Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line,” Blood, vol. 67, no. 4, pp. 925–930, 1986.
- S. Koizumi, H. Seki, and T. Tachinami, “Malignant clonal expansion of large granular lymphocytes with a Leu-11+, Leu-7- surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2,” Blood, vol. 86, no. 5, pp. 1065–1073, 1986.
- C. J. Froelich, V. M. Dixit, and X. Yang, “Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases,” Immunology Today, vol. 19, no. 1, pp. 30–36, 1998.
- M. B. Barrie, H. W. Stout, M. S. Abougergi, B. C. Miller, and D. L. Thiele, “Antiviral cytokines induce hepatic expression of the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor 6,” Journal of Immunology, vol. 172, no. 10, pp. 6453–6459, 2004.
- B. A. Bladergroen, C. J. L. M. Meijer, R. L. Ten Berge et al., “Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?” Blood, vol. 99, no. 1, pp. 232–237, 2002.
- C. S. Ng, S. T. H. Lo, J. K. C. Chan, and W. C. Chan, “CD56+ putative natural killer cell lymphomas: production of cytolytic effectors and related proteins mediating tumor cell apoptosis?” Human Pathology, vol. 28, no. 11, pp. 1276–1282, 1997.
- K. Aozasa, T. Takakuwa, T. Hongyo, and W. I. Yang, “Nasal NK/T-cell lymphoma: epidemiology and pathogenesis,” International Journal of Hematology, vol. 87, no. 2, pp. 110–117, 2008.
- T. Takakuwa, Z. Dong, S. Nakatsuka et al., “Frequent mutations of Fas gene in nasal NK/T cell lymphoma,” Oncogene, vol. 21, no. 30, pp. 4702–4705, 2002.
- M. Yamaguchi, K. Kita, H. Miwa et al., “Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells,” Cancer, vol. 76, no. 11, pp. 2351–2356, 1995.
- Y. H. Ko, H. J. Ree, W. S. Kim, W. H. Choi, W. S. Moon, and S. W. Kim, “Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans,” Cancer, vol. 89, no. 10, pp. 2106–2116, 2000.
- Y. H. Ko, K. E. Choi, J. H. Han, J. M. Kim, and H. J. Ree, “Comparative genomic hybridization study of nasal-type NK/T-cell lymphoma,” Communications in Clinical Cytometry, vol. 46, no. 2, pp. 85–91, 2001.
- L. L. Siu, V. Chan, J. K. C. Chan, K. F. Wong, R. Liang, and Y. L. Kwong, “Consistent patterns of allelic loss in natural killer cell lymphoma,” American Journal of Pathology, vol. 157, no. 6, pp. 1803–1809, 2000.
- L. L. Siu, K. F. Wong, J. K. C. Chan, and Y. L. Kwong, “Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia: recognition of consistent patterns of genetic alterations,” American Journal of Pathology, vol. 155, no. 5, pp. 1419–1425, 1999.
- H. S. Sun, I. J. Su, Y. C. Lin, J. S. Chen, and S. Y. Fang, “A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma,” British Journal of Haematology, vol. 122, no. 4, pp. 590–599, 2003.
- J. Yoon and Y. H. Ko, “Deletion mapping of the long arm of chromosome 6 in peripheral T and NK cell lymphomas,” Leukemia and Lymphoma, vol. 44, no. 12, pp. 2077–2082, 2003.
- J. Iqbal, C. Kucuk, R. J. deLeeuw et al., “Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies,” Leukemia, vol. 23, no. 6, pp. 1139–1151, 2009.
- A. Kuma, M. Hatano, M. Matsui et al., “The role of autophagy during the early neonatal starvation period,” Nature, vol. 432, no. 7020, pp. 1032–1036, 2004.
- M. M. Hippert, P. S. O'Toole, and A. Thorburn, “Autophagy in cancer: good, bad, or both?” Cancer Research, vol. 66, no. 19, pp. 9349–9351, 2006.
- M. E. Ray, G. Wistow, Y. A. Su, P. S. Meltzer, and J. M. Trent, “AIM1, a novel non-lens member of the βγ-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 3229–3234, 1997.
- G. A. Martins, L. Cimmino, M. Shapiro-Shelef et al., “Transcriptional repressor Blimp-1 regulates T cell homeostasis and function,” Nature Immunology, vol. 7, no. 5, pp. 457–465, 2006.
- C. A. Turner Jr., D. H. Mack, and M. M. Davis, “Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells,” Cell, vol. 77, no. 2, pp. 297–306, 1994.
- L. Pasqualucci, M. Compagno, J. Houldsworth et al., “Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 311–317, 2006.
- G. L. Semenza, “Hif-1 and human disease: one highly involved factor,” Genes and Development, vol. 14, no. 16, pp. 1983–1991, 2000.
- P. J. Jost and J. Ruland, “Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications,” Blood, vol. 109, no. 7, pp. 2700–2707, 2007.
- J. E. Darnell Jr., I. M. Kerr, and G. R. Stark, “Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins,” Science, vol. 264, no. 5164, pp. 1415–1421, 1994.
- Q. Zhang, P. N. Raghunath, L. Xue et al., “Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma,” Journal of Immunology, vol. 168, no. 1, pp. 466–474, 2002.
- P. Coppo, V. Gouilleux-Gruart, Y. Huang et al., “STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma,” Leukemia, vol. 23, no. 9, pp. 1667–1678, 2009.
- P. P. Piccaluga, C. Agostinelli, A. Califano et al., “Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 823–834, 2007.
- T. Wang, G. Niu, M. Kortylewski et al., “Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells,” Nature Medicine, vol. 10, no. 1, pp. 48–54, 2004.
- D. Rotin and S. Kumar, “Physiological functions of the HECT family of ubiquitin ligases,” Nature Reviews Molecular Cell Biology, vol. 10, no. 6, pp. 398–409, 2009.
- R. Schmitz, M. L. Hansmann, V. Bohle et al., “TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma,” Journal of Experimental Medicine, vol. 206, no. 5, pp. 981–989, 2009.
- L. Quintanilla-Martinez, M. Kremer, G. Keller et al., “p53 mutations in nasal natural killer/t-cell lymphoma from mexico: association with large cell morphology and advanced disease,” American Journal of Pathology, vol. 159, no. 6, pp. 2095–2105, 2001.
- M. Li, D. Chen, A. Shiloh et al., “Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization,” Nature, vol. 416, no. 6881, pp. 648–653, 2002.
- M. Kimura, Y. Matsuda, T. Eki et al., “Assignment of STK6 to human chromosome 20q13.2→q13.1 and a pseudogene STK6P to 1q41→q42,” Cytogenetics and Cell Genetics, vol. 79, no. 3-4, pp. 201–203, 1997.
- L. Zhang, M. S. Anglesio, M. O'Sullivan et al., “The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers,” Nature Medicine, vol. 13, no. 9, pp. 1060–1069, 2007.
- M. S. Anglesio, V. Evdokimova, N. Melnyk et al., “Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney,” Human Molecular Genetics, vol. 13, no. 18, pp. 2061–2074, 2004.
- J. Zhao, Z. Zhang, Z. Vucetic, K. J. Soprano, and D. R. Soprano, “HACE1: a novel repressor of RAR transcriptional activity,” Journal of Cellular Biochemistry, vol. 107, no. 3, pp. 482–493, 2009.
- T. Bowman, R. Garcia, J. Turkson, and R. Jove, “STATs in oncogenesis,” Oncogene, vol. 19, no. 21, pp. 2474–2488, 2000.
- J. F. Bromberg, M. H. Wrzeszczynska, G. Devgan et al., “Stat3 as an oncogene,” Cell, vol. 98, no. 3, pp. 295–303, 1999.
- R. Chiarle, W. J. Simmons, H. Cai et al., “Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target,” Nature Medicine, vol. 11, no. 6, pp. 623–629, 2005.
- A. Zamo, R. Chiarle, R. Piva et al., “Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death,” Oncogene, vol. 21, no. 7, pp. 1038–1047, 2002.
- H. Yu, M. Kortylewski, and D. Pardoll, “Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment,” Nature Reviews Immunology, vol. 7, no. 1, pp. 41–51, 2007.
- M. Kortylewski, M. Kujawski, T. Wang et al., “Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity,” Nature Medicine, vol. 11, no. 12, pp. 1314–1321, 2005.
- C. Zou, J. Ma, X. Wang et al., “Lack of Fas antagonism by Met in human fatty liver disease,” Nature Medicine, vol. 13, no. 9, pp. 1078–1085, 2007.
- B. K. Hadland, N. R. Manley, D. M. Su et al., “γ-secretase inhibitors repress thymocyte development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7487–7491, 2001.
- T. Palomero, M. L. Sulis, M. Cortina et al., “Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia,” Nature Medicine, vol. 13, no. 10, pp. 1203–1210, 2007.
- E. Chanudet, H. Ye, J. Ferry et al., “A20 deletion is associated with copy number gain at the TNFAIBIC locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands,” Journal of Pathology, vol. 217, no. 3, pp. 420–430, 2009.
- L. L. Siu, J. K. C. Chan, K. F. Wong, and Y. L. Kwong, “Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved,” American Journal of Pathology, vol. 160, no. 1, pp. 59–66, 2002.
- V. Rouget-Quermalet, J. Giustiniani, A. Marie-Cardine et al., “Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas,” Oncogene, vol. 25, no. 19, pp. 2807–2811, 2006.
- M. Ito, T. Maruyama, N. Saito, S. Koganei, K. Yamamoto, and N. Matsumoto, “Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 289–295, 2006.
- J. R. Bischoff and G. D. Plowman, “The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis,” Trends in Cell Biology, vol. 9, no. 11, pp. 454–459, 1999.
- H. Katayama, K. Sasai, H. Kawai et al., “Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53,” Nature Genetics, vol. 36, no. 1, pp. 55–62, 2004.
- H. G. Drexler and Y. Matsuo, “Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma,” Leukemia, vol. 14, no. 5, pp. 777–782, 2000.
- S. Zhao, Q. L. Tang, M. X. He et al., “A novel nude mice model of human extranodal nasal type NK/T-cell lymphoma,” Leukemia, vol. 22, no. 1, pp. 170–178, 2008.